HDAC Inhibitors Potentiate Doxorubicin Cytotoxicity in HepG2 Cells and Alter DNA-Repair- and p53-Associated Transcriptional Programs
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27209091 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Kaidi Guo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Genomics, GROW-Research Institute for Oncology and Reproduction, Maastricht University, 6229 ER Maastricht, The Netherlan…. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Doxorubicin, Tumor Suppressor Protein p53, DNA Repair. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ZonMw, The Dutch Organisation for knowledge and innovation in health, healthcare and well-being, Dutch Science Organization.
Abstract (Originalsprache)
Histone deacetylase inhibitors (HDACis) can enhance responses to DNA-damaging chemotherapy, but how they alter doxorubicin (DOX)-induced transcriptional programs remains incompletely understood. We investigated the effects of valproic acid (VPA) and vorinostat (SAHA) on DOX cytotoxicity and associated molecular responses in HepG2 cells. HDAC inhibition, cell viability, apoptosis, and DOX IC50 values were assessed using histone H3 acetylation, cell counting, Alamar Blue assays, and cleaved caspase-3 immunofluorescence. Transcriptomic responses were analyzed by RNA sequencing, differential expression analysis, and Hallmark gene set enrichment analysis, with selected findings evaluated by RT-qPCR, Western blotting, and comparison with published CRISPR/Cas9 DOX-response data. Both HDAC inhibitors increased histone H3 acetylation and enhanced DOX cytotoxicity, markedly reducing DOX IC50 values. VPA co-treatment also increased DOX-induced cleaved caspase-3 signaling. RNA-seq showed broad transcriptional remodeling, including depletion of the DNA-repair gene set following VPA treatment and attenuation of canonical p53-responsive genes during HDACi–DOX co-treatment. Several HDACi-repressed DNA-repair genes overlapped with genes whose loss sensitized cells to DOX in a published CRISPR screen. HDAC inhibition therefore enhances DOX cytotoxicity and is accompanied by alterations in DNA-repair-associated and p53-responsive transcriptional programs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Genomics, GROW-Research Institute for Oncology and Reproduction, Maastricht University, 6229 ER Maastricht, The Netherlands.
ORCID-Profile: Florian Caiment, Twan van den Beucken
Förderung
- ZonMw, The Dutch Organisation for knowledge and innovation in health, healthcare and well-being
- Dutch Science Organization
Zitieren
APA
Guo, K., van Herwijnen, M., Caiment, F., & van den Beucken, T. (2026). HDAC Inhibitors Potentiate Doxorubicin Cytotoxicity in HepG2 Cells and Alter DNA-Repair- and p53-Associated Transcriptional Programs. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27209091
Vancouver
Guo K, van Herwijnen M, Caiment F, van den Beucken T. HDAC Inhibitors Potentiate Doxorubicin Cytotoxicity in HepG2 Cells and Alter DNA-Repair- and p53-Associated Transcriptional Programs. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27209091
BibTeX
@article{Guo2026,
author = {Guo, Kaidi and van Herwijnen, Marcel and Caiment, Florian and van den Beucken, Twan},
title = {HDAC Inhibitors Potentiate Doxorubicin Cytotoxicity in HepG2 Cells and Alter DNA-Repair- and p53-Associated Transcriptional Programs},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27209091}
}
EUVIMED